greeksoup/ stocks
Stocks / India / DRREDDY / Announcements

Dr. Reddy's Laboratories Ltd. announcements

In the twelve months since 23 September 2025 Dr. Reddy's Laboratories Ltd. made 144 announcements to NSE under Regulation 30: 31 general updates, 22 analysts/institutional investor meet/con. call updates, 18 copy of newspaper publication, 15 press release, 9 updates, 8 news verification. The latest, on 22 September 2026, was filed under trading window; the table carries the company's own summary of each and the PDF.

DateCategoryWhat the company told the exchangeFiling
22 September 2026Trading WindowDr. Reddy's Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF
21 September 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetPDF
18 September 2026Arrangements for strategic, technical, manufacturing, or marketing tie upDr. Reddy's Laboratories Limited has today, i.e., September 18, 2026, entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited for Qdenga® in the private market in India.PDF
18 September 2026News VerificationThe Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned Dr Reddy s gets voluntary licence for Gilead s once-yearly HIV prevention drug. The response from the Company is attached.PDF
17 September 2026News VerificationThe Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned Dr Reddy s gets voluntary licence for Gilead s once-yearly HIV prevention drug. The response from the Company is awaited.PDF
16 September 2026Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
11 September 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
10 September 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Allotment of Employee Stock optionsPDF
10 September 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetPDF
26 August 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Allotment of employee stock optionsPDF
20 August 2026Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
14 August 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
14 August 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
13 August 2026Resignation of Director/KMP/SMPDr. Reddy's Laboratories Limited has informed the Exchange about Resignation of Director/KMP/SMPPDF
13 August 2026Change in ManagementDr. Reddy's Laboratories Limited has informed the Exchange about change in ManagementPDF
7 August 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
1 August 2026Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated August 01, 2026, titled "Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015".PDF
29 July 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
29 July 2026News VerificationThe Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned Dr Reddys antibiotic gets Thailand approval six months after US nod. The response from the Company is attached.PDF
28 July 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about TranscriptPDF
28 July 2026News VerificationThe Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned Dr Reddys antibiotic gets Thailand approval six months after US nod. The response from the Company is awaited.PDF
23 July 2026Change in AuditorsDr. Reddy's Laboratories Limited has informed the Exchange regarding Change in Auditors of the company.PDF
23 July 2026Change in Director(s)Dr. Reddy's Laboratories Limited has informed the Exchange regarding Change in Director(s) of the company.PDF
23 July 2026Shareholders meetingDr. Reddy's Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 23, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.PDF
23 July 2026Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
23 July 2026Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated July 23, 2026, titled "Intimation of Earnings call recording".PDF
22 July 2026Investor PresentationDr. Reddy's Laboratories Limited has informed the Exchange about Investor PresentationPDF
22 July 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about allotment of Employee Stock OptionsPDF
22 July 2026Change in ManagementDr. Reddy's Laboratories Limited has informed the Exchange about change in ManagementPDF
22 July 2026Outcome of Board MeetingDr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.PDF
15 July 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Conference call TranscriptPDF
13 July 2026Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated July 13, 2026, titled "Intimation of Earnings call".PDF
10 July 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Link of RecordingPDF
9 July 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Conference CallPDF
9 July 2026General UpdatesDisclosure under Regulation 30 of SEBI (LODR) Regulations, 2015PDF
3 July 2026Certificate under SEBI (Depositories and Participants) Regulations, 2018Dr. Reddy's Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF
1 July 2026Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
30 June 2026UpdatesDr. Reddy's Laboratories Limited has informed the Exchange regarding 'Letter to shareholders in relation to Integrated Annual Report of the Company for FY 2025-26'.PDF
30 June 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Integrated Annual Report FY 2026PDF
30 June 2026UpdatesDr. Reddy's Laboratories Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report FY 2026'.PDF
30 June 2026Shareholders meetingDr. Reddy's Laboratories Limited has informed the Exchange regarding Notice of 42nd Annual General Meeting to be held on July 23, 2026PDF
25 June 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
22 June 2026Trading WindowDr. Reddy's Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF
20 June 2026Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Newspaper advertisement titled Notice of the 42nd Annual General Meeting to be held through video conference, record date and final dividend informationPDF
19 June 2026UpdatesDr. Reddy's Laboratories Limited has informed the Exchange regarding 'Allotment of Employee stock options'.PDF
13 June 2026Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated Jun 13, 2026, titled "Dr. Reddy s announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States.".PDF
12 June 2026Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
12 June 2026Disclosure under SEBI Takeover RegulationsKallam Satish Reddy has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.PDF
10 June 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetPDF
5 June 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Allotment of Employee Stock OptionsPDF
3 June 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of Analyst/Investor meetPDF
1 June 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange aboutPDF
30 May 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange that the Annual Report in Form 20F for the fiscal year ended March 31, 2026 has been filed with United States Securities and Exchange Commission.PDF
28 May 2026Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Dr. Reddy's Laboratories to Ring the Closing Bell® at the New York Stock Exchange.PDF
27 May 2026Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
18 May 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about TranscriptPDF
16 May 2026Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada".PDF
13 May 2026Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
12 May 2026Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated May 12, 2026, titled "Recordings of Earnings call".PDF
12 May 2026Investor PresentationDr. Reddy's Laboratories Limited has informed the Exchange about Investor PresentationPDF
12 May 2026Change in ManagementDr. Reddy's Laboratories Limited has informed the Exchange about elevation of Mr. Sandeep Khandelwal as a Senior Management Personnel.PDF
12 May 2026Change in Director(s)Dr. Reddy's Laboratories Limited has informed the Exchange regarding Change in Director(s) of the company.PDF
12 May 2026Change in AuditorsDr. Reddy's Laboratories Limited has informed the Exchange regarding Change in Auditors of the company.PDF
12 May 2026Record DateDr. Reddy's Laboratories Limited has informed the Exchange that Record date for the purpose of Final Dividend is 10-Jul-2026.PDF
12 May 2026DividendDr. Reddy's Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 12, 2026, recommended Final Dividend of Rs. 8 per equity share.PDF
12 May 2026Outcome of Board MeetingDr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.PDF
11 May 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetPDF
11 May 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Grant of Employee Stock OptionsPDF
29 April 2026Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvalsDr. Reddy's Laboratories Limited has informed the Exchange about Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvalsPDF
24 April 2026Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated April 24, 2026, titled "Intimation of Earnings call".PDF
24 April 2026Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
24 April 2026News VerificationThe Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned Dr. Reddys Laboratories still awaiting approval for a major near-term trigger, sources say. The response from the Company is attached.PDF
24 April 2026Rumour Verification - Regulation 30(11)Dr. Reddy's Laboratories Limited has informed the Exchange about Rumour Verification - Regulation 30(11)PDF
23 April 2026News VerificationThe Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned Dr. Reddys Laboratories still awaiting approval for a major near-term trigger, sources say. The response from the Company is awaited.PDF
16 April 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Board meeting intimation for recommending final dividend, if any, for Financial Year 2025-26PDF
14 April 2026Action(s) taken or orders passedDr. Reddy's Laboratories Limited has informed the Exchange about Dr. Reddy s Laboratories LLC, Russia, a step-down wholly-owned subsidiary has received a final penalty decision from the Tax Authority.PDF
8 April 2026Certificate under SEBI (Depositories and Participants) Regulations, 2018Dr. Reddy's Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF
7 April 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about sale of wholly owned subsidiaryPDF
26 March 2026UpdatesDr. Reddy's Laboratories Limited has informed the Exchange regarding 'Allotment of Employee Stock Options'.PDF
24 March 2026UpdatesDr. Reddy's Laboratories Limited has informed the Exchange regarding 'Revised Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information.'PDF
23 March 2026Trading WindowDr. Reddy's Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF
21 March 2026Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Dr. Reddy s Laboratories announces launch of India s first DCGI-approved Semaglutide injection Obeda® for Type 2 Diabetes.".PDF
17 March 2026Action(s) taken or orders passedDr. Reddy's Laboratories Limited has informed the Exchange about Action(s) taken or orders passedPDF
13 March 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
12 March 2026Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
12 March 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Allotment of Employee Stock OptionsPDF
10 March 2026Rumour Verification - Regulation 30(11)Dr. Reddy's Laboratories Limited has informed the Exchange about Rumour Verification - Regulation 30(11)PDF
10 March 2026Change in ManagementDr. Reddy's Laboratories Limited has informed the Exchange about change in ManagementPDF
6 March 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
5 March 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
27 February 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetPDF
24 February 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
18 February 2026Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated February 18, 2026, titled "Dr. Reddy's forays into Hormone Replacement Therapy segment with acquisition of Progynova® and Cyclo- Progynova® in India".PDF
17 February 2026UpdatesDr. Reddy's Laboratories Limited has informed the Exchange regarding 'Allotment of Employee Stock Options'.PDF
12 February 2026Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
12 February 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetPDF
9 February 2026ResignationDr. Reddy's Laboratories Limited has informed the Exchange regarding Resignation of Mr Sushrut Kulkarni as Other of the company w.e.f. May 08, 2026.PDF
2 February 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetPDF
27 January 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about TranscriptPDF
24 January 2026Action(s) initiated or orders passedDr. Reddy's Laboratories Limited has informed the Exchange about Action(s) initiated or orders passedPDF
22 January 2026Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
21 January 2026Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Link of RecordingPDF
21 January 2026Investor PresentationDr. Reddy's Laboratories Limited has informed the Exchange about Investor PresentationPDF
21 January 2026Outcome of Board MeetingDr. Reddy's Laboratories Limited has submitted to the Exchange, unaudited financial results for the quarter and nine months ended December 31, 2025.PDF
14 January 2026Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated January 14, 2026, titled "Dr. Reddy s announces the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the generic equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.".PDF
10 January 2026General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015PDF
8 January 2026Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated January 08, 2026, titled "Intimation of Earnings call".PDF
6 January 2026Certificate under SEBI (Depositories and Participants) Regulations, 2018Dr. Reddy's Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF
6 January 2026Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
1 January 2026Action(s) taken or orders passedDr. Reddy's Laboratories Limited has informed the Exchange about Action(s) taken or orders passedPDF
31 December 2025UpdatesDr. Reddy's Laboratories Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015'.PDF
23 December 2025Trading WindowDr. Reddy's Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF
17 December 2025Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
16 December 2025Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetPDF
12 December 2025General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
12 December 2025Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetPDF
12 December 2025Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated December 12, 2025, titled "Dr. Reddy s Laboratories announces Science-Based Net Zero Climate Targets".PDF
9 December 2025General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
8 December 2025Arrangements for strategic, technical, manufacturing, or marketing tie upDr. Reddy's Laboratories Limited has informed the Exchange about Arrangements for strategic, technical, manufacturing, or marketing tie upPDF
2 December 2025Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetPDF
28 November 2025Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetPDF
26 November 2025General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
26 November 2025General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
24 November 2025Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated November 24, 2025, titled "Dr. Reddy s receives European Commission approval for AVT03 (denosumab), a proposed Biosimilar of Prolia® and Xgeva®".PDF
18 November 2025Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetPDF
18 November 2025Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
17 November 2025Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meetPDF
14 November 2025General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
13 November 2025General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about Allotment of 7,430 Equity Shares on exercise of Stock Options under ESOPsPDF
11 November 2025News VerificationThe Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned Hackers dupe Dr Reddy's Laboratories of ₹2.16 crore here's how the cyber fraud unfolded. The response from the Company is attached.PDF
10 November 2025News VerificationThe Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned Hackers dupe Dr Reddy's Laboratories of ₹2.16 crore here's how the cyber fraud unfolded. The response from the Company is awaited.PDF
10 November 2025Change in ManagementDr. Reddy's Laboratories Limited has informed the Exchange about change in ManagementPDF
5 November 2025Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
30 October 2025Analysts/Institutional Investor Meet/Con. Call UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about TranscriptPDF
29 October 2025UpdatesDr. Reddy's Laboratories Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015'.PDF
25 October 2025Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
25 October 2025UpdatesDr. Reddy's Laboratories Limited has informed the Exchange regarding 'Earnings call recordings'.PDF
24 October 2025General UpdatesUpdate on Senior Management PersonnelPDF
24 October 2025Investor PresentationDr. Reddy's Laboratories Limited has informed the Exchange about Investor PresentationPDF
24 October 2025Outcome of Board MeetingDr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.PDF
21 October 2025General UpdatesDr. Reddy's Laboratories Limited has informed the Exchange about General UpdatesPDF
13 October 2025Press ReleaseDr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 13, 2025, titled "Initmation of Earnings call".PDF
7 October 2025Copy of Newspaper PublicationDr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper PublicationPDF
1 October 2025Certificate under SEBI (Depositories and Participants) Regulations, 2018Dr. Reddy's Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF

Regulation 30 of SEBI's listing regulations requires a company to tell the exchange of material events; the category is the exchange's, the words are the company's own summary as filed, cut to a few lines, and the PDF is the full filing.

Source

Corporate announcements on nseindia.com for DRREDDY.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install